| Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials RC Doebele, A Drilon, L Paz-Ares, S Siena, AT Shaw, AF Farago, ... The Lancet Oncology 21 (2), 271-282, 2020 | 1505 | 2020 |
| Colon cancer, version 2.2021, NCCN clinical practice guidelines in oncology AB Benson, AP Venook, MM Al-Hawary, MA Arain, YJ Chen, KK Ciombor, ... Journal of the National Comprehensive Cancer Network 19 (3), 329-359, 2021 | 1133 | 2021 |
| NCCN guidelines insights: colon cancer, version 2.2018 AB Benson, AP Venook, MM Al-Hawary, L Cederquist, YJ Chen, ... Journal of the National Comprehensive Cancer Network 16 (4), 359-369, 2018 | 923 | 2018 |
| Pancreatic cancer: from state-of-the-art treatments to promising novel therapies I Garrido-Laguna, M Hidalgo Nature reviews Clinical oncology 12 (6), 319-334, 2015 | 641 | 2015 |
| PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring PIK3CA Mutations F Janku, JJ Wheler, SN Westin, SL Moulder, A Naing, AM Tsimberidou, ... Journal of clinical oncology 30 (8), 777-782, 2012 | 526 | 2012 |
| A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer M Hidalgo, E Bruckheimer, NV Rajeshkumar, I Garrido-Laguna, ... Molecular cancer therapeutics 10 (8), 1311-1316, 2011 | 476 | 2011 |
| NCCN guidelines insights: rectal cancer, version 6.2020: featured updates to the NCCN guidelines AB Benson, AP Venook, MM Al-Hawary, MA Arain, YJ Chen, KK Ciombor, ... Journal of the National Comprehensive Cancer Network 18 (7), 806-815, 2020 | 433 | 2020 |
| PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors F Janku, AM Tsimberidou, I Garrido-Laguna, X Wang, R Luthra, DS Hong, ... Molecular cancer therapeutics 10 (3), 558-565, 2011 | 430 | 2011 |
| Rectal cancer, version 2.2022, NCCN clinical practice guidelines in oncology AB Benson, AP Venook, MM Al-Hawary, N Azad, YJ Chen, KK Ciombor, ... Journal of the National Comprehensive Cancer Network 20 (10), 1139-1167, 2022 | 382 | 2022 |
| From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer C Nevala-Plagemann, M Hidalgo, I Garrido-Laguna Nature reviews Clinical oncology 17 (2), 108-123, 2020 | 319 | 2020 |
| Personalizing Cancer Treatment in the Age of Global Genomic Analyses: PALB2 Gene Mutations and the Response to DNA Damaging Agents in Pancreatic Cancer MC Villarroel, NV Rajeshkumar, I Garrido-Laguna, A De Jesus-Acosta, ... Molecular cancer therapeutics 10 (1), 3-8, 2011 | 294 | 2011 |
| Metastatic pancreatic cancer: ASCO clinical practice guideline update DPS Sohal, EB Kennedy, A Khorana, MS Copur, CH Crane, ... Journal of Clinical Oncology 36 (24), 2545-2556, 2018 | 286 | 2018 |
| Tumor engraftment in nude mice and enrichment in stroma-related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer I Garrido-Laguna, M Uson, NV Rajeshkumar, AC Tan, E De Oliveira, ... Clinical Cancer Research 17 (17), 5793-5800, 2011 | 277 | 2011 |
| Sotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer JH Strickler, H Satake, TJ George, R Yaeger, A Hollebecque, ... New England journal of medicine 388 (1), 33-43, 2023 | 242 | 2023 |
| PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers F Janku, JJ Lee, AM Tsimberidou, DS Hong, A Naing, GS Falchook, S Fu, ... PloS one 6 (7), e22769, 2011 | 239 | 2011 |
| Metastatic pancreatic cancer: ASCO guideline update DPS Sohal, EB Kennedy, P Cinar, T Conroy, MS Copur, CH Crane, ... Journal of Clinical Oncology 38 (27), 3217-3230, 2020 | 234 | 2020 |
| TIGIT: a novel immunotherapy target moving from bench to bedside BL Solomon, I Garrido-Laguna Cancer Immunology, Immunotherapy 67 (11), 1659-1667, 2018 | 178 | 2018 |
| Novel therapeutic targets in non-small cell lung cancer F Janku, I Garrido-Laguna, LB Petruzelka, DJ Stewart, R Kurzrock Journal of Thoracic Oncology 6 (9), 1601-1612, 2011 | 163 | 2011 |
| Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models G Feldmann, A Mishra, S Bisht, C Karikari, I Garrido-Laguna, Z Rasheed, ... Cancer biology & therapy 12 (7), 598-609, 2011 | 145 | 2011 |
| Small bowel adenocarcinoma, version 1.2020, NCCN clinical practice guidelines in oncology AB Benson, AP Venook, MM Al-Hawary, MA Arain, YJ Chen, KK Ciombor, ... Journal of the National Comprehensive Cancer Network 17 (9), 1109-1133, 2019 | 140 | 2019 |
